@Article{Doboszyńska2005,
journal="Przewodnik Lekarza/Guide for GPs",
issn="1505-8409",
year="2005",
title="Inhaled corticosteroids and long acting  \β2-agonists in asthma and chronic obstructive pulmonary disease (COPD)",
abstract="Agonists of \β 2  receptors are the most potent bronchial dilators. Available long-acting \β 2 -agonists are widely used in the treatment of both bronchial asthma and COPD. However, administration of these drugs alone is rather disadvantageous because of the risk of tachyphylaxis. Other group of medicines used in the bronchial asthma and COPD are inhaled glucorticosteroids. They are the first choice drugs in asthma therapy and their effectiveness is well documented. If, however, they are ineffective is the  administered dose, its increase does not bring about desired effect. In such a situation addition of the  long-acting \β 2 -agonists accelerate stabilization of the disease course. Recently, several papers were  published, positively assessing the use of such a combined therapy in COPD. An effect of both  components are considered additive and not simply summed up.",
author="Doboszyńska, Anna",
pages="90--95",
url="https://www.termedia.pl/Inhaled-corticosteroids-and-long-acting-946-2-agonists-in-asthma-and-chronic-obstructive-pulmonary-disease-COPD-,8,3670,1,1.html"
}